Table 5.
Effect of buprenorphine on the plasma pharmacokinetic parameters of atazanavir and ritonavir
| Atazanavir Parameter | ATV | ATV-BUP/NLX | p-value |
|---|---|---|---|
| AUC0-24 (h*ng/mL) | 29863 (4696) | 20649 (2206) | n.s. |
| CI/F (L/h) | 16.5 (2.32) | 21.64 (2.60) | n.s. |
| Cmax (ng/mL) | 4435 (410) | 3223 (494) | n.s. |
| Tmax (h) | 2.00 (1.45-4.00) | 3.00 (1.50-6.05) | n.s. |
| Cmin (ng/mL) |
259 (100) |
173 (41) |
n.s. |
|
Atazanavir/ritonavir Parameter |
ATV |
ATV-BUP/NLX |
|
| AUC0-24 (h*ng/mL) | 55980 (7653) | 56137 (3783) | n.s. |
| CI/F (L/h) | 5.78 (0.70) | 5.62 (0.47) | n.s. |
| Cmax (ng/mL) | 5359 (501) | 4597 (346) | n.s. |
| Tmax (h) | 3.00 (1.50-4.00) | 3.00 (1.50-6.00) | n.s. |
| Cmin (ng/mL) |
1072 (269) |
1223 (136) |
n.s. |
| RTV | RTV-BUP/NLX | ||
| AUC0-24 (h*ng/mL) | 9460 (1330) | 9730 (1310) | n.s. |
| CI/F (L/h) | 12.68 (1.88) | 12.77 (2.35) | n.s. |
| Cmax (ng/mL) | 1490 (170) | 1240 (180) | n.s. |
| Tmax (h) | 4.00 (2.00-4.00) | 4.00 (2.00-8.00) | n.s. |
| Cmin (ng/mL) | <200 | <200 | n.s. |
Note: Values are the mean (standard error of the mean) for 10 subjects who participated in both sessions, except that the discontinuous variable, Tmax, is given as median (range). Student's unpaired t-test was used to determine p-values for all parameters except Tmax, where the Wilcoxon test was used.